A new study reveals the combination of three drugs, i.e., an anti-epileptic, which is casually used, a contraceptive steroid, and a cholesterol-reducing agent. This combination can form a fruitful and anti-toxic treatment for truculent blood cancers.
A random clinical trial was taken to test the combo, i.e., a new drug against another agent (danazol) in the patient having myelodysplastic syndromes (MSD). They experimented with the new drug, and for this new drug experiment, the University of Birmingham scientist has given over 1million fund award to run this experiment.
Fight Against Cancer With The Triple-Drug Weapon
Cancer is known as one of the prime ailments that people have to suffer across the globe. With this new research, the patients can have better health over a period and slow down the overall development of cancer cells in the body.
The new combination of medicines can help the patient of boo dancer get better and quick cure said an expert from the research team.
With this (MSD) myelodysplastic syndrome, many of them die due to this MSD turn into aggressive acute myeloid leukaemia (AML).
AML is a hostile blood cancer. Generally, when this acute myeloid leukaemia occurs, it is not that fatal, it is poor, but when acute myeloid leukaemia arises through myelodysplastic syndrome, it will worsen.
With this acute myeloid leukaemia, if patients are left untreated, they will die because AML leads to destroying the production of normal red blood corpuscles. Acute myeloid is common and frequent in elderly people-intensive chemotherapy is a traditional treatment; many of them cannot tolerate the treatment because of their age, capability, and as they are fragile too.
Scientists at the University of Birmingham, they already discovered the combination of these drugs- bezafibrate, which is used for cholesterol-lowering, medroxyprogesterone acetate it is a contraceptive steroid, these drugs relieved a wide range of blood cancers, including acute myeloid leukaemia, chronic lymphocytic leukaemia, and non-Hodgkin’s lymphoma which can cause quick fatal.
Some clinical trials have shown that for those two drugs BEZ and MPA, the addition of one more drug called valproic acid in a low dose can form a trio. This trio will enhance the death of acute myeloid leukaemia cells. By giving this triple-drug combo (VIP), it will cause a cancer-busting impact which is equally similar to BEZ and MPA, which are given in high doses.
Co-author Chris bunce, a professor, said that to treat conditions outside of their approval by using existing drugs indicates the approach to produce low toxicity therapies. We believe in treating the patients in the early stage with low toxic therapy will be most effective, and this is the clinical strategy they use and recommend. They even believe that this method can improve patient outcomes.
A low dose of BaP can produce a non-toxic side effect, and it is highly recommended who cannot have chemotherapy due to their condition. This low dose of BaP has helped in raising the blood cells- clinical trial has proved this.
Due to patients being fragile because of their age, reduced renal function, and due to their already existing diseases, prior chemotherapy, the duel combo in high dose are not well tolerated in treatment drFarhatkhanim said that there was a major challenge in their last BaP trials. They have been focused all the time on elderly patients due to their intolerance to intense therapy like chemotherapy; these are not patient options.
For many of these cancer patients, there are only a few options of treatment; they are not like other diseases which will have many options, can the disease is life-threatening also. Therefore, this trio combination may cause a profound impact on survival from deadly cancers.
